Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Irinotecan in Recurrent Malignant Glioma
NCT00283556Phase 2Completed
- Sponsor
- Kentuckiana Cancer Institute
- Start
- Aug 2001
- Primary completion
- Dec 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in malignant glioma, sponsored by Kentuckiana Cancer Institute. Started Aug 2001; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00283556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283556.